Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Breast 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1012Lung Neoplasms 769Small Cell Lung Carcinoma 159Breast Neoplasms 73Adenocarcinoma of Lung 68Neoplasms 67Colorectal Neoplasms 50NSCLC 49Melanoma 48Stomach Neoplasms 46Pleural Effusion, Malignant 46Pancreatic Neoplasms 45Brain Neoplasms 42Mesothelioma, Malignant 41Ovarian Neoplasms 32Prostatic Neoplasms 31Neoplasm Metastasis 31Head and Neck Neoplasms 30Mesothelioma 28Esophageal Neoplasms 27Carcinoma, Renal Cell 24Carcinoma 24Urinary Bladder Neoplasms 23Lung Diseases 22Colonic Neoplasms 22Thoracic Neoplasms 19Liver Neoplasms 19Thymoma 18Carcinoma, Hepatocellular 18Pleural Effusion 17

Interventions

Rhenium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasm Recurrence, Local × Thoracic × Clear all
NCT00100256 2022-11-07

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

Andarix Pharmaceuticals

Phase 1/2 Unknown
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Recurrence, Local, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡